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The role of the cytokine interleukin-6 (IL-6) in metabolic homeostasis is the subject of conjecture. Recent
work in Nature Medicine (Ellingsgaard et al., 2011) demonstrates that IL-6 released from skeletal muscle
during exercise mediates crosstalk between insulin-sensitive tissues, intestinal L cells, and pancreatic islets
to adapt to changes in insulin demand.The debate regarding the pathological
versus beneficial nature of IL-6 in metab-
olism remains unclear and the subject
of continuing debate (Mooney, 2007; Ped-
ersen and Febbraio, 2007). On one hand,
increased IL-6 in obesity is associated
with the physiopathology of type 2 dia-
betes (Klover et al., 2003), while on the
other, muscle-derived IL-6 appears to
contribute to improved glycemia following
exercise (Pedersen and Febbraio, 2008).
A recent study published in Nature Medi-
cine (Ellingsgaard et al., 2011) makes
a telling contribution to our understanding
of this apparent paradox. The authors
found that IL-6, released from either con-
tracting skeletal muscle or white adipose
tissue, stimulatedglucagon-likepeptide-1
(GLP-1) from the gut and the pancreas.
As GLP-1 is a hormone that induces
insulin secretion, this complex organ-
to-organ crosstalk provides strong evi-
dence that IL-6 is a cytokine that has
positive effects on maintaining glucose
homeostasis.
The basic concept that IL-6 is an inflam-
matory cytokine that leads to insulin resis-
tance was first challenged with the finding
that skeletal muscle releases IL-6 during
contraction (Steensberg et al., 2000) to
act in an endocrine-like manner (Febbraio
et al., 2004). Since this discovery, IL-6 has
been found to increase glucose uptake
and fat oxidation in skeletal muscle and
improve glucose tolerance and insulin
sensitivity (Carey et al., 2006; van Hall
et al., 2003), effects that oppose those
seen in the development of metabolic
syndrome. The recent paper by Donath
and colleagues (Ellingsgaard et al., 2011)
neatly demonstrates that IL-6 mediated
increases in GLP-1 secretion from L cells
in the intestine and a cells in the pancreas8 Cell Metabolism 15, January 4, 2012 ª2012that led to improved b cell function, insulin
secretion, and glycemic control. This
study is the first to provide evidence of
a previously unknown link between IL-6
secretion from insulin-sensitive tissues
and the beneficial effects of GLP-1 on
insulin action. By using IL-6 knockout
mice and coadministration of an IL-6 anti-
body, this recent paper (Ellingsgaard
et al., 2011) demonstrated that the exer-
cise-induced increase in GLP-1 was IL-6
dependent. Furthermore, IL-6 was unable
to improve glucose tolerance in mice
lacking the GLP-1 receptor or mice
treated with the GLP-1 receptor antago-
nist, exendin (9-39). Interestingly, in addi-
tion to acute administration of IL-6, the
authors were also able to demonstrate
improved glycemia and glucose tolerance
following twice daily injections of IL-6 for
7 days. These effects were associated
with increases in synthesis and expres-
sion of circulating GLP-1. Significantly,
pancreatic GLP-1, insulin, and glucagon
content were also increased with IL-6
administration, along with insulin secre-
tion from the islets of treated mice.
It is well known that exercise improves
insulin action in the immediate postexer-
cise period (Wojtaszewski et al., 2000),
but until now the mechanism has been
unclear. Two important experiments in
the current study (Ellingsgaard et al.,
2011) provide new and important informa-
tion on the phenomenon of enhanced
postexercise insulin action. First, IL-6-
deficient mice displayed no improvement
in glucose tolerance postexercise, and
second, the improvement was seen only
when the glucose tolerance test was
administered orally, not intraperitoneally,
indicative of the dependence on GLP-1.
This study supports the notion thatElsevier Inc.skeletal muscle is an endocrine organ,
capable of secreting metabolically active
proteins termed ‘‘myokines’’ (Pedersen
and Febbraio, 2008).
As the role of IL-6 in obesity and
metabolic disease is controversial, the
authors sought to investigate whether
additional administration of IL-6 could im-
prove b cell function in overfed, insulin-
resistant, and diabetic animals. Exoge-
nous IL-6 improved glucose tolerance
and insulin secretion in high-fat-fed
ob/ob and db/dbmice. By way of support
for the proposed IL-6/GLP-1 b cell mech-
anism, high-fat-fed mice whose b cells
were destroyed with streptozotocin failed
to improve insulin secretion with adminis-
tration of IL-6. Additionally, endogenous
IL-6 in db/db mice was blocked with
an IL-6 antibody treatment. Increased
fasting glucose levels and decreased glu-
cose tolerance were reported in animals
treated with the IL-6 antibody, as well as
lowered glucagon levels and undetect-
able GLP-1 levels. GLP-1 content in the
pancreas of treated animals was also
lower than in control mice. Importantly,
analysis of high-fat-fed mice found that
IL-6 was required for the high-fat-diet-
induced expansion of a cell mass and
increases in pancreatic GLP-1 content
and subsequent insulin secretion.
This paper highlights the importance of
organ crosstalk and may offer an addi-
tional therapeutic target for the modula-
tion of glucose metabolism in obesity
and diabetes. However, these findings
still need to be interpreted with caution.
There are still many instances in the litera-
ture that suggest that IL-6 may be detri-
mental to maintaining metabolic homeo-
stasis in obesity. While the study by
Ellingsgaard et al. (2011) adds weight to
Figure 1. The Pleiotropic Metabolic Effects of the Cytokine IL-6
IL-6 is released from contracting skeletal muscle and adipose tissue to trigger
GLP-1 release from the gut and the pancreas to improve glucose tolerance.
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elevated in obesity in order to
counteract other more del-
eterious factors associated
with obesity, the pleiotropic
nature of IL-6 makes thera-
peutic strategies difficult.
In summary, the work by
Donath and colleagues has
provided crucial data that
adipose tissue-derived IL-6
in obesity and diabetes as
well as skeletal muscle IL-6
during exercise mediate the
production and secretion of
GLP-1 from the intestine and
pancreas, leading to an en-
hanced insulin response and
improved glycemia (see Fig-
ure 1). This study provides
further evidence of the impor-
tance of IL-6 in glucose
metabolism and uncovers its
previously unknown role in
linking adipose tissue, skel-
etal muscle, intestines, and
pancreas through GLP-1.Moreover, the study strengthens the
concept that the skeletal muscle is an
endocrine organ, capable of secreting
factors that can affect not only the
adipose tissue and the liver, but also the
gut, pancreas, and perhaps many other
organs. The work opens the door to the
identification of other skeletal musclesecretory factors that may modulate
metabolic processes.ACKNOWLEDGMENTS
M.A.F. is a Senior Principal Research Fellow of the
National Health and Medical Research Council of
Australia.Cell Metabolism 15, JanuaryREFERENCES
Carey, A.L., Steinberg, G.R.,
Macaulay, S.L., Thomas, W.G.,
Holmes, A.G., Ramm,G., Prelovsek,
O., Hohnen-Behrens, C., Watt, M.J.,
James, D.E., et al. (2006). Diabetes
55, 2688–2697.
Ellingsgaard, H., Hauselmann, I.,
Schuler, B., Habib, A.M., Baggio,
L.L.,Meier,D.T.,Eppler,E.,Bouzakri,
K., Wueest, S., Muller, Y.D., et al.
(2011). Nat. Med. 17, 1481–1489.
Febbraio, M.A., Hiscock, N., Sac-
chetti, M., Fischer, C.P., and Peder-
sen, B.K. (2004). Diabetes 53, 1643–
1648.
Klover, P.J., Zimmers, T.A., Konia-
ris, L.G., and Mooney, R.A. (2003).
Diabetes 52, 2784–2789.
Mooney, R.A. (2007). J. Appl.
Physiol. 102, 816–818, discussion
818–819.
Pedersen, B.K., and Febbraio, M.A.
(2007). J. Appl. Physiol. 102,
814–816.
Pedersen, B.K., and Febbraio, M.A.
(2008). Physiol. Rev. 88, 1379–1406.
Steensberg, A., van Hall, G., Osada,
T., Sacchetti, M., Saltin, B., andKlarlund Pedersen, B. (2000). J. Physiol. 529,
237–242.
van Hall, G., Steensberg, A., Sacchetti, M., Fischer,
C., Keller, C., Schjerling, P., Hiscock, N., Møller, K.,
Saltin, B., Febbraio, M.A., and Pedersen, B.K.
(2003). J. Clin. Endocrinol. Metab. 88, 3005–3010.
Wojtaszewski, J.F., Hansen, B.F., Gade, Kiens, B.,
Markuns, J.F., Goodyear, L.J., and Richter, E.A.
(2000). Diabetes 49, 325–331.4, 2012 ª2012 Elsevier Inc. 9
